Prognostic and predictive factors in resected non-small-cell lung cancer

Bibliography

• Ponn RB, Lo Cicero J III, Daly BDT. Surgical treatment of non small cell lung cancer. In: Shields TW, Lo Cicero J III, Ponn R, Rusch VW, editors, General thoracic surgery. 6th edition. Williams and Wilkins, Philadelphia, Lippincott; 2005. p. 1548-87
   Google Scholar
• Wright G, Manser RL, Byrnes G, Surgery for early-stage non-small cell lung cancer: systemic review and meta-analysis of randomized enrolled trials. Thorax 2006;61:597-603
   PubMed Web of Science ®Google Scholar
• Strauss GM. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. Hematol Oncol Clin North Am 2005;19:263-81
   PubMed Web of Science ®Google Scholar
• Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer. A decade of progress. Chest 2002;122:1037-57
   PubMed Web of Science ®Google Scholar
• Volker M, Mone MJ, Kamakar P, Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 2001;8:213-24
   PubMed Web of Science ®Google Scholar
• Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group1: gene expression and platinum resistance. Int J Mol Med 2004;14:959-70
   PubMed Web of Science ®Google Scholar
• Simon GR, Sharma S, Cantor A, ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-83
   PubMed Web of Science ®Google Scholar
• Olaussen KA, Dunant A, Fouret P, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91
   PubMed Web of Science ®Google Scholar
• Vilmar A, Santoni-Rugiu E, Sorensen JB. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial. Eur J Cancer 2010;46:1554-62
   Google Scholar
• Stubbe J. Ribonucleotide reductase in the twenty-first century. Proc Natl Acad Sci USA 1998;95:2723-4
   PubMed Web of Science ®Google Scholar
• Zheng Z, Chen T, Li X, DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8
   PubMed Web of Science ®Google Scholar
• Bepler G, Kusmartseva I, Sharma S, RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-7
   PubMed Web of Science ®Google Scholar
• Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360:1007-14
   PubMed Web of Science ®Google Scholar
• Rosell R, Skrzypski M, Jassem E, BRCA1: a novel prognostic factor in resected non-small cell lung cancer. PLoS one 2007;2:e1129
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Hamajima N, Ogawa M, Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97
   PubMed Web of Science ®Google Scholar
• Tsao MS, Aviel-Ronen S, Ding K, Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-7
   PubMed Web of Science ®Google Scholar
• Ricardo VL, Lori AE, Long J, P27Kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-23
   PubMed Web of Science ®Google Scholar
• Tsukamoto S, Sugio K, Sakada T, Reduced expression of cell-cycle regulator p27Kip1 correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 2001;34:83-90
   PubMed Web of Science ®Google Scholar
• Filipits M, Pirker R, Dunant A, Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25:2735-40
   PubMed Web of Science ®Google Scholar
• St Croix B, Florenes VA, Rak JW, Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-10
   PubMed Web of Science ®Google Scholar
• Eymin B, Haugg M, Droin N, P27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999;18:1411-18
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, van de Wetering ML, Mooi WJ, Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-35
   PubMed Web of Science ®Google Scholar
• Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999;20:1507-10
   PubMed Web of Science ®Google Scholar
• Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614-20
   PubMed Web of Science ®Google Scholar
• Hockenbery D, Nunez G, Milliman C, Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6
   PubMed Web of Science ®Google Scholar
• Martin S, Paesmans M, Berghmans T, Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003;89:55-64
   PubMed Web of Science ®Google Scholar
• Renouf DJ, Wood-Baker R, Ionescu DN, BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009;4:486-91
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
   PubMed Web of Science ®Google Scholar
• Shibuya M, Claesson WL. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312:549-60
   PubMed Web of Science ®Google Scholar
• Zhan P, Wang J, Lv XJ, Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009;4:1094-103
   PubMed Web of Science ®Google Scholar
• Fontanini G, Lucchi M, Vignati S, Angiogenesis is a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-6
   PubMed Web of Science ®Google Scholar
• Pastorino U, Andreola S, Tagliabue E, Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65
   PubMed Web of Science ®Google Scholar
• Yano T, Tanikawa S, Fujie T, Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 2000;36:601-9
   PubMed Web of Science ®Google Scholar
• Kara K, Oriuchi N, Shimizu K, Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 2009;100:753-8
   PubMed Web of Science ®Google Scholar
• Meert AP, Paesmans M, Martin B, The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002;87:694-701
   PubMed Web of Science ®Google Scholar
• Mineo TC, Ambrogi V, Baldi A, Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 2004;57:591-7
   PubMed Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Imai H, Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 2009;66:120-6
   PubMed Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Imai H, Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 2009;100:249-54
   Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Imai H, CD98 expression is associated with poor prognosis in resected non-small cell lung cancer with lymph node metastasis. Ann Surg Oncol 2009;16:3473-81
   PubMed Web of Science ®Google Scholar
• Trivella M, Pezzella F, Pastorino U, Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncol 2007;8:488-99
   PubMed Web of Science ®Google Scholar
• Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22
   PubMed Web of Science ®Google Scholar
• Martin B, Paesmans M, Mascaux C, Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-25
   PubMed Web of Science ®Google Scholar
• Imai H, Kaira K, Oriuchi N, L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology 2009;54:804-13
   PubMed Web of Science ®Google Scholar
• Mcloud TC, Bourgouin PM, Greenberg RW, Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-23
   PubMed Web of Science ®Google Scholar
• Shim SS, Lee KS, Kim BT, Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-19
   PubMed Web of Science ®Google Scholar
• Pieterman RM, van Putten JW, Meuzelaar JJ, Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61
   PubMed Web of Science ®Google Scholar
• Lardinois D, Weder W, Hany TF, Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7
   PubMed Web of Science ®Google Scholar
• Sasaki R, Komaki R, Macapinlac H, [18F] fluorodexyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-43
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Stroobants SG, Dupont PJ, Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography in non-small cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999;17:3201-6
   PubMed Web of Science ®Google Scholar
• Berghmans T, Dusart M, Paesmans M, Primary tumor standardized uptake value (SUVmax) measured on fluorodexyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12
   PubMed Web of Science ®Google Scholar
• Brock CS, Meikle SR, Price P. Dose fluorine-18 fluorodexyglucose metabolic imaging of tumor benefit oncology? Eur J Nucl Med 1997;24:691-705
   PubMedGoogle Scholar
• Hoffman JM, Waskin HA, Schifter T, The use of FDG-PET in differentiating infectious from malignant central nervous system lesions in patients with AIDS. J Nucl Med 1992;33:838
   Google Scholar
• Higashi K, Ueda Y, Sakurai A, Correlation of Glut-1 glucose transporter expression with [18F] FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000;27:1778-85
   Google Scholar
• Chung JH, Cho KJ, Lee SS, Over expression of Glut 1 in lymphoid follicles correlates with false-positive 18F-FDG PET results in lung cancer staging. J Nucl Med 2004;45:999-1003
   PubMed Web of Science ®Google Scholar
• Vleugel MM, Greijer AE, Shvarts, Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol 2005;58:172-7
   PubMed Web of Science ®Google Scholar
• Elson DA, Ryan HE, Snow JW, Coordinate up-regulation of hypoxia inducible factor (HIF)-1a and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing 1. Cancer Res 2000;60:6189-95
   PubMed Web of Science ®Google Scholar
• van Baardwijk A, Dooms C, van Suylen RJ, The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8
   PubMed Web of Science ®Google Scholar
• Younes M, Brown RW, Stephenson M, Over expression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51
   PubMed Web of Science ®Google Scholar
• De Greus-Oei F, van Krieken JH, Aliredjo RP, Biological correlation of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87
   PubMed Web of Science ®Google Scholar
• Hung JJ, Yang MH, Hsu HS, Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 2009;64:1082-9
   PubMed Web of Science ®Google Scholar
• Tsurutani J, Fukuoka J, Tsurutani H, Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006;24:306-14
   PubMed Web of Science ®Google Scholar
• David O, Jett J, LeBeau H, Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004;10:6865-71
   PubMed Web of Science ®Google Scholar
• Hirami Y, Aoe M, Tsukuda K, Relation of epidermal growth factor receptor, phosphorylated Akt, and hypoxia-inducible factor-1 alpha in non-small cell lung cancers. Cancer Lett 2004;214:157-64
   PubMed Web of Science ®Google Scholar
• Lee SH, kim HS, Park WS, Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002;110:587-92
   PubMed Web of Science ®Google Scholar
• Massion PP, Taflan PM, Shyr Y, Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 2004;170:1088-94
   PubMed Web of Science ®Google Scholar
• Mukohara T, Kudoh S, Matsuura K, Activated Akt expression has significant correlation with EGFR and TGF-alpha expression in stage I NSCLC. Anticancer Res 2004;24:11-17
   PubMed Web of Science ®Google Scholar
• Mukohara T, Kudoh S, Yamauchi S, Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 2003;41:123-30
   PubMed Web of Science ®Google Scholar
• Balsara BR, Pei J, Mitsuuchi Y, Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053-9
   PubMed Web of Science ®Google Scholar
• Tsao AS, McDonnell T, Lam S, Increased phosphor-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention study. Cancer Epidemiol Biomarkers Prev 2003;12:660-4
   PubMed Web of Science ®Google Scholar
• Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005;37:19-24
   PubMed Web of Science ®Google Scholar
• Dhillon T, Mauri FA, Bellezza G, Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 2010;5:314-19
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Bepler G, Syrigos G, High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin cancer Res 2009;12:4157-64
   Google Scholar
• Kosaka T, Yatabe Y, Endoh H, Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer res 2004;64:8919-23
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;35:2129-39
   Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Onozato R, Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009;4:22-9
   PubMed Web of Science ®Google Scholar
• Kamal NS, Soria JC, Mendiboure J, MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 2010;16:1206-15
   PubMed Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Otani Y, Diagnostic usefulness of fluorine–18-alpha–methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007;131:1019-27
   PubMed Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Otani Y, Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathological study. Clin Cancer Res 2007;13:6369-78
   PubMed Web of Science ®Google Scholar
• Tomiyoshi K, Amed K, Muhammad S, Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-alpha-methyl tyrosine using separation and purification system. Nucl Med Commun 1997;18:169-75
   PubMed Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Shimizu K, 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med 2009;50:1770-6
   PubMed Web of Science ®Google Scholar
• Kaira K, Oriuchi N, Imai H, Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008;98:742-8
   PubMed Web of Science ®Google Scholar
• Peyrollier K, Hajduch E, Blair AS, L-Leucine availability regulates phosphatidylinositol 3-kinase, p70S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-ragulation of system A amino acid transport. Biochem J 2000;350:361-8
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Sakurai H, Kimura T, System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett 2009;276:95-101
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinma. N Engl J Med 2009;361:947-57
   PubMed Web of Science ®Google Scholar